Equillium Reports Q3 2026 Results, $53.3 Million in Cash and EQ504 Trial Progress

Equillium reported a third-quarter 2026 net loss of $4.6 million, or $0.04 per share, and cash and cash equivalents of $53.3 million at September 30. After approximately $20 million in gross proceeds received in October, the company reported a pro forma cash balance of approximately $72.0 million a…